Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study
Abstract Introduction Psoriasis is a chronic inflammatory skin disorder, affecting around 2–3% of the global population. The IL-23/Th17 signaling pathway plays a critical role in disease progression. Guselkumab, an IL-23p19 monoclonal antibody, has shown substantial efficacy in clinical trials for t...
Saved in:
| Main Authors: | Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, Matteo Megna, Annunziata Raimondo, Giacomo Caldarola, Nicoletta Bernardini, Anna Balato, Anna Campanati, Maria Esposito, Claudio Bonifati, Viviana Lora, Luca Potestio, Serena Lembo, Francesco Loconsole, Eleonora De Luca, Nevena Skroza, Dario Buononato, Tommaso Bianchelli, Maria Concetta Fargnoli, Nello Tommasino, Felice Primavera, Clara De Simone, Luca Bianchi, Marco Galluzzo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-04-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-025-01394-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2025-07-01) -
The use of guselkumab in psoriatic arthritis: evidence from real clinical practice
by: N. V. Nekrasova, et al.
Published: (2021-12-01) -
Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison
by: Leyla Baykal Selçuk, et al.
Published: (2025-04-01) -
Successful treatment of pyoderma gangrenosum with guselkumab
by: Sofia Botvid, et al.
Published: (2025-03-01) -
Successful treatment of generalized pustular psoriasis with guselkumab
by: Martina Part
Published: (2024-12-01)